Revolution Medicines今日夜盘股价大幅上涨17.76%，引起了市场的高度关注。
消息面上，此次大涨与即将召开的美国临床肿瘤学会（ASCO）年会密切相关。市场预期，ASCO大会将集中展示公司核心候选药物daraxonrasib在III期RASolute 302研究中的详细数据。该研究评估了该口服RAS抑制剂对比化疗，用于治疗经治的转移性胰腺导管腺癌患者的效果。
此前公布的顶线数据显示，daraxonrasib治疗组的中位总生存期达到13.2个月，而化疗对照组仅为6.7个月，生存期几乎实现翻倍。鉴于胰腺癌是公认最难攻克的癌症之一，五年相对生存率仅约13%，这一突破性数据被视为RAS靶向治疗领域的重大里程碑。市场在ASCO正式报告发布前，已提前反映了对该公司研发管线及未来前景的强烈乐观情绪。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.